Vertex Pharmaceuticals/VRTX
$445.21
1.03%-
1D1W1MYTD1YMAX
About Vertex Pharmaceuticals
Vertex Pharmaceuticals Incorporated is a global biotechnology company. The Company is focused on investing in scientific innovation to create transformative medicines for people with serious diseases, with a focus on specialty markets. It has four approved medicines that treat the underlying cause of cystic fibrosis (CF), and one approved therapy that treats severe sickle cell disease (SCD) and transfusion dependent beta thalassemia (TDT). Its pipeline includes clinical-stage programs in CF, SCD, TDT, acute and neuropathic pain, APOL1-mediated kidney disease, type 1 diabetes, myotonic dystrophy type 1 and alpha-1 antitrypsin deficiency. Its marketed medicines are TRIKAFTA/KAFTRIO, SYMDEKO/SYMKEVI (tezacaftor/ivacaftor and ivacaftor), ORKAMBI (lumacaftor/ivacaftor) and KALYDECO (ivacaftor). It is developing non-autologous (allogeneic) fully differentiated, stem-cell derived islet cell therapies designed to replace insulin-producing islet cells that are destroyed in people with T1D.
Ticker
VRTX
Sector
Healthcare
Trading on
NASDAQ
Industry
Biotechnology & Drugs
CEO
Jeffrey Leiden
Employees
5,400
Headquarters
Boston, United States
Website
www.vrtx.com
VRTX Metrics
BasicAdvanced
$113B
Market cap
28.38
P/E ratio
$15.42
EPS
0.40
Beta
-
Dividend rate
Price and volume
Market cap
$113B
Beta
0.40497
52-week high
$448.40
52-week low
$320.01
Average daily volume
1M
Financial strength
Current ratio
3.501
Quick ratio
3.287
Long term debt to equity
1.949
Total debt to equity
1.949
Enterprise value to free cash flow
27.484
Management effectiveness
Return on assets (TTM)
18.74%
Return on equity (TTM)
24.38%
Return on investment (TTM)
22.29%
Valuation
Price to earnings (TTM)
28.38
Price to revenue (TTM)
11.085
Price to book
6.093
Price to tangible book (TTM)
6.791
Price to free cash flow (TTM)
32.448
Growth
Revenue change (TTM)
10.61%
Earnings per share change (TTM)
22.8%
3-year revenue growth
16.73%
3-year earnings per share growth
10.51%
What the Analysts think about VRTX
Analyst Ratings
Majority rating from 32 analysts.
Price Targets
Average projection from 25 analysts.
High $577.00
Low $325.00
$445.21
Current price
$467.42
Average price target
VRTX Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$2.7B
6.87%
Net income
$1.1B
13.5%
Profit margin
40.86%
6.21%
VRTX Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
$3.89
$4.08
$4.20
$4.76
-
Expected
$3.88
$3.97
$4.10
$4.06
$4.18
Surprise
0.21%
2.67%
2.37%
17.15%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.
Upcoming events
FAQs
What’s the current market cap for Vertex Pharmaceuticals stock?
Vertex Pharmaceuticals (VRTX) has a market cap of $115B as of May 20, 2024.
What is the P/E ratio for Vertex Pharmaceuticals stock?
The price to earnings (P/E) ratio for Vertex Pharmaceuticals (VRTX) stock is 28.88 as of May 20, 2024.
Does Vertex Pharmaceuticals stock pay dividends?
No, Vertex Pharmaceuticals (VRTX) stock does not pay dividends to its shareholders as of May 20, 2024.
When is the next Vertex Pharmaceuticals dividend payment date?
Vertex Pharmaceuticals (VRTX) stock does not pay dividends to its shareholders.
What is the beta indicator for Vertex Pharmaceuticals?
Vertex Pharmaceuticals (VRTX) has a beta rating of 0.41. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.
What is the Vertex Pharmaceuticals stock price target?
The target price for Vertex Pharmaceuticals (VRTX) stock is $467.42, which is 4.99% above the current price of $445.21. This is an average based on projections from 25 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.
Buy or sell Vertex Pharmaceuticals stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.